Borderline Products — When Peptides Become Medicinal

The MHRA uses the 'borderline products' concept to describe substances that may or may not fall under medicines law. Peptides sit awkwardly in this space.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

The borderline concept

Some substances do not obviously sit inside or outside the medicinal-product definition. They may be cosmetics, food supplements, biocides, medical devices — or medicines, depending on how they are presented and used.

Three factors that push a peptide into the medicinal side

• Claims. Therapeutic, prophylactic, or diagnostic claims push a product towards medicinal-product status.
• Presentation. Vials, ampoules, dose strengths in micrograms or milligrams, and packaging that mimics pharmaceuticals all read as medicinal presentation.
• Function. A substance with significant pharmacological, immunological, or metabolic action — even without claims — can be a medicinal product.

Why peptides are so often borderline

Peptides are typically high-potency, receptor-targeted, and sold in injection-style presentations. They have obvious functional properties. They are often marketed with claim-like language even when packaging carries a disclaimer.

Implications

The borderline status is not a stable, comfortable category — it is a risk zone. A product that is borderline today can be reclassified as medicinal tomorrow, with enforcement consequences for sellers and possible legal consequences for buyers in some scenarios.

What this means for readers

The category is unstable enough that anyone treating an unapproved peptide as a quasi-licensed medicine is taking on risk they cannot characterise. Decisions about therapy belong with a clinician, not with a vendor or a forum.

This is not legal advice.